Prostate Cancer News and Research

Latest Prostate Cancer News and Research

HealthLinx's OvPlex performs better over CA125 in part 1 of multinational ovarian cancer biomarker study

Diagnostic company HealthLinx Limited reports that initial analysis of part 1 of its multinational ovarian cancer biomarker study confirms a statistically significant increase in diagnostic performance of OvPlex™ over CA125 alone. Enhanced performance of OvPlex™ was also established specifically for early stage (Stage I-II) disease.

16 Dec 2010

Scientists discover potential strategy for pancreatic cancer therapy

By determining what goes missing in human cells when the gene that is most commonly mutated in pancreatic cancer gets turned on, Johns Hopkins scientists have discovered a potential strategy for therapy.

15 Dec 2010

Study suggests unexpected role for NLRP3 protein in cancer vaccine development

The promise of vaccines targeted against various types of cancer has raised the hopes of patients and their families. The reality, however, is that these promising treatments are difficult to develop. One of the challenges is identifying a discrete cellular target to stop cancer growth without inactivating the immune system. Scientists at UNC Lineberger Comprehensive Cancer Center report a laboratory finding that has the potential to increase the effectiveness of therapeutic cancer vaccines.

15 Dec 2010

Genes predict survival time, potential new treatments for patients with non-small cell lung cancer

Researchers at UT Southwestern Medical Center have discovered sets of genes active in cancer cells and normal tissue that predict survival time and potential new treatments for patients with non-small cell lung cancer.

15 Dec 2010

Chinese hospital uses UNIQUE radiotherapy system to treat cancer patients

Prince of Wales Hospital in Hong Kong, China, has become the first treatment center in Asia to commence treating cancer patients using the UNIQUE™ medical linear accelerator from Varian Medical Systems (NYSE: VAR).

14 Dec 2010

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

BETHESDA, Md.,GTx, Inc. this weekend presented results of the Capesaris™ (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial at the Annual Meeting of the Society of Urologic Oncology.

14 Dec 2010

South Korean FDA approves EDAP's new Sonolith i-move lithotripter

EDAP TMS SA, the global leader in therapeutic ultrasound, reported today the approval of its new lithotripter Sonolith i-move by South-Korean Food and Drug Administration (KFDA).

13 Dec 2010

ORNL's software scans molecular databases, may help scientists to develop new drug treatments

A quicker and cheaper technique to scan molecular databases developed at the Department of Energy's Oak Ridge National Laboratory could put scientists on the fast track to developing new drug treatments.

13 Dec 2010

Pomegranate juice exhibits potential to prevent metastasis of prostate cancer cells to the bone

Researchers at the University of California, Riverside have identified components in pomegranate juice that both inhibit the movement of cancer cells and weaken their attraction to a chemical signal that promotes the metastasis of prostate cancer to the bone. The research could lead to new therapies for preventing cancer metastasis.

13 Dec 2010

Prostate cancer study identifies 295 genes associated with clinical recurrence following radical prostatectomy

Genomic Health, Inc. today announced the first results of a large prostate cancer study that identified 295 genes strongly associated with clinical recurrence following radical prostatectomy. Top-line findings from this study, which applied the same RT-PCR technology used in Genomic Health's Oncotype DX® breast and colon cancer tests, will be presented today at the Society for Urologic Oncology (SUO) annual meeting.

13 Dec 2010

Expert discusses androgen deprivation therapy for prostate cancer

A common prostate cancer treatment, the ‘androgen deprivation therapy’ has often been prescribed for low-risk prostate cancer patients. This therapy for treating prostate cancer had previously been blamed for increased risk of cardiovascular disease and heart conditions.

9 Dec 2010

WSJ investigation: A sharp rise in specific prostate therapy parallels high Medicare payments

Roughly one in three Medicare beneficiaries diagnosed with prostate cancer today gets a sophisticated form of radiation therapy called IMRT. …The story behind the sharp rise in the use of IMRT — which stands for intensity-modulated radiation therapy — is about more than just the rapid adoption of a new medical technology.

9 Dec 2010

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.

9 Dec 2010

MassMutual broadens life insurance underwriting guidelines for prostate cancer survivors

Building on a long-standing commitment to helping people before, during and after a cancer diagnosis, Massachusetts Mutual Life Insurance Company has broadened its life insurance underwriting guidelines for prostate cancer survivors.

8 Dec 2010

Bavarian Nordic receives SPA for Phase 3 study of PROSTVAC for advanced prostate cancer

Bavarian Nordic A/S announced today that the company has received a letter of concurrence from the U.S. Food and Drug Administration on a Special Protocol Assessment for a Phase 3 study required for product registration for its product candidate, PROSTVAC, for the treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

8 Dec 2010

Researchers develop imaging technology that can accurately identify prostate cancer

Prostate cancer is the most common type of cancer among men, but its diagnosis has up to now been inaccurate and unpleasant. Researchers at Eindhoven University of Technology in the Netherlands, in cooperation with AMC Amsterdam, have developed an imaging technology that can accurately identify tumors.

8 Dec 2010

First Edition: December 8, 2010

Today's health policy headlines include more detail on the deal reached to avoid a scheduled cut in physician's Medicare pay.

8 Dec 2010

Ultraviolet light activates enzyme that helps skin cancer cells survive, proliferate: Researchers

The sun's ultraviolet light activates an enzyme that helps skin cancer cells survive and proliferate, researchers report.

8 Dec 2010

Protein alpha-2-beta-1 integrin suppresses metastasis

Mary Zutter and colleagues, at Vanderbilt University Medical Center, Nashville, have generated data that lead them to suggest that decreased expression of the protein alpha-2 integrin is predictive of tumor dissemination to distant sites and decreased survival in individuals with either breast or prostate cancer.

7 Dec 2010

Frisky old men - still keen and active: Sex study

According to the latest Australian study, men at 75 and older have not said good bye to their sex lives yet. They found that nearly one third of these older men were sexually active at least once a year -- including about 1 in 10 men aged 90 to 95. Many of these men have agreed that they would want more of sex and those not sexually active are blaming health issues, low testosterone or lack of partners. The findings appear in the Dec. 7 issue of the Annals of Internal Medicine.

6 Dec 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

HealthLinx's OvPlex performs better over CA125 in part 1 of multinational ovarian cancer biomarker study

Scientists discover potential strategy for pancreatic cancer therapy

Study suggests unexpected role for NLRP3 protein in cancer vaccine development

Genes predict survival time, potential new treatments for patients with non-small cell lung cancer

Chinese hospital uses UNIQUE radiotherapy system to treat cancer patients

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

South Korean FDA approves EDAP's new Sonolith i-move lithotripter

ORNL's software scans molecular databases, may help scientists to develop new drug treatments

Pomegranate juice exhibits potential to prevent metastasis of prostate cancer cells to the bone

Prostate cancer study identifies 295 genes associated with clinical recurrence following radical prostatectomy

Expert discusses androgen deprivation therapy for prostate cancer

WSJ investigation: A sharp rise in specific prostate therapy parallels high Medicare payments

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

MassMutual broadens life insurance underwriting guidelines for prostate cancer survivors

Bavarian Nordic receives SPA for Phase 3 study of PROSTVAC for advanced prostate cancer

Researchers develop imaging technology that can accurately identify prostate cancer

First Edition: December 8, 2010

Ultraviolet light activates enzyme that helps skin cancer cells survive, proliferate: Researchers

Protein alpha-2-beta-1 integrin suppresses metastasis

Frisky old men - still keen and active: Sex study

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in